Health experts have expressed interest in interest voltage after the FDA drug leader stopped a top job in Big Pharma.
Pfizer announced this week that Dr. Patrizia Cavazzoni, former director of the FDA's Center for Drug Evaluation and Research (Cder), will join the company as Chief Medical Officer.
Although the exact salary is unknown, sites for vacancies suggest that the position pays up to $ 500,000 a year before bonuses, more than the $ 400,000 a year that the president of the United States makes.
The relocation comes in the middle of the new chosen health leader Robert F Kennedy Junior, who has accused the FDA of being obliged to influence the industry, because almost two -thirds of the financing of the agency comes from the pharmaceutical companies that regulates.
Health experts told DailyMail.com Dr. Cavazzoni's new message 'proves RFK JR's Point' about the 'rotating door' between health authorities and Big Pharma.
Dr. Cavazzoni held her position in Cder from 2020 to last month and just before President Donald Trump returned to the office and the nomination of Robert F Kennedy JR as Ministry of Health and Human Services Secretary.
Dr. Cavazzoni, who previously worked at Pfizer before he came to the FDA in 2018, is the latter in a long line of former health officials who jump for Big Pharma.
Dr. Patrizia Cavazzoni, former director of the FDA Center for Drug Evaluation and Research (Cder), will join Pfizer as Chief Medical Officer, the company has announced this week
Robert F Kennedy JR, depicted here, has accused the FDA of corruption and is too mandatory to the influence of the industry, because almost two -thirds of the financing of the agency comes from pharmaceutical companies
Former FDA commissioner Dr. Robert Califf, who served under President Barack Obama and President Joe Biden, moved from the Agency to Google Health and the spider of the spin -off Life Sciences after Trump was chosen the first time.
Dr. Scott Gottlieb, FDA Commissioner during the first Trump administration, is now on the Pfizer board.
Dr. Carole Lieberman, a psychiatrist in Beverly Hills who also has a degree in public health, mentioned the timing of the new appointment of Dr. Cavazzoni 'shocking' and said it could lead to a potential conflict of interest.
She told DailyMail.com: 'It only proves the point of RFK JR that the FDA and Big Pharma are in bed together.
“It would be expected that Dr. Cavazzoni waited until the “ink was dry” for his confirmation before taking this step and made the headlines.
'This will hollow the confidence that Americans in the FDA and Big Pharma will have even more because people will realize that [the FDA] Let medicines simply be labeled as “FDA approved” without doing enough research to test their safety. '
The FDA currently receives around 65 percent of its financing from pharmaceutical companies such as Pfizer, including those who may request approval of drugs or medical devices.
Neal K Shah, founder and CEO of Careyaya and Counterforce Health, told DailyMail.com that Dr. Appointment. Cavazzoni illustrates the ongoing “rotating door” between the FDA and Big Pharma.
Just like Dr. He also warned Lieberman that the move 'a further validation is of the long -term criticism of RFK JR on the compromised independence and integrity of the FDA', because agencies can be more biased and probably approve drugs that have not yet been correctly tested or proven safe.
Shah said: 'When FDA officials work in the industry, they will probably make decisions that prefer the pharmaceutical companies with which they have previous associations and have future ties.
'This is specific dangers for a health care sector where safety is of the utmost importance.
“Former supervisors may be too cozy with their former employers to enforce the kind of difficult standards that are sometimes needed.”
The worries reflect those of surrounding previous FDA officials with ties with pharmaceutical companies.
Dr. Robert Califf, FDA Commissioner under Presidents Obama and Biden, had to make ethical concessions about his ties with the pharmaceutical industry before he could protect votes to lead the agency a second time
Dr. Asem Malhotra, a British cardiologist who is viewed for a top advice role in addition to RFK JR (he is on the right with RFK JR), has proposed that the FDA receives none of his financing from Big Pharma to eliminate bias to eliminate bias
When former President Biden Dr. Califf nominated to lead the FDA for the second time, politicians and other critics accused him of bias because he had served as an advisor for Google Health and the Life Life Sciences during the first Trump administration.
After his nomination, Dr. Califf Ethics make concessions to Senator Elizabeth Warren (D-Mass) to secure her voice, which means that he had to admit that his past ties were more likely to make biased choices.
As part of the agreement, he promised not to request work or compensation from companies with drugs or medical devices that he had dealt with as a commissioner for four years.
He also swore to take a step back of things that may have been involved in his former employers or customers for four years.
It is unclear whether Dr. Gottlieb is mandatory as similar conditions as an FDA boss who has become Pfizer Board member.
Experts who wrote in the British Medical Journal last year also expressed their concern about such movements and called the connection a 'rotating door'.
Dr. ASEEM MALHOTRA, a British cardiologist who is viewed for a top advice role in addition to RFK JR, has proposed to eliminate bias by looking directly at financing.
He previously told DailyMail.com that the FDA may not receive his budget from Big Pharma, because officials should not be afraid 'biting the hand she feeds'.
“You can't repair healthcare without removing company interests,” he said.
Shah called on the FDA to set up 'more responsible gateway' to keep health agencies that serve the public interest on the interests of pharmaceutical giants.
He said: “The financing of the FDA from the industry costs too high costs.”
